Magle Group Approves Multi-Centre Clinical Trial in Genicular Artery Embolisation for Osteoarthritis Pain Relief
Magle Group is proud to announce that its approved the initiation of a multi-centre clinical trial to explore the use of EmboCept® S in Genicular Artery Embolisation (GAE), a minimally-invasive procedure aimed at delivering immediate and long-term pain relief for patients suffering from osteoarthritis (OA) of the knee.
This innovative treatment, performed by interventional radiologists using advanced imaging techniques, targets blood flow to the synovium—the lining of the knee—reducing inflammation and alleviating pain without the need for surgery.
This trial represents a significant milestone for Magle Group, providing an opportunity to extend the application of its proprietary degradable starch microsphere (DSM) technology into the growing field of embolisation therapies. EmboCept® S, already established in other areas of embolisation, leverages DSM’s unique properties to enhance both efficacy and patient safety compared to traditional embolic agents.
A Growing Market Opportunity
Osteoarthritis is a leading cause of disability worldwide, with millions of patients seeking alternative treatments as conventional options such as medication and surgery often come with limitations and risks. GAE offers a promising new solution that addresses these challenges, making it an attractive market segment with high growth potential. Magle Group’s entry into this space aligns with its mission to develop innovative, patient-centric technologies that improve clinical outcomes.
The Uniqueness of DSM Technology
Magle’s DSM technology sets itself apart in the field of embolisation by being fully degradable, biocompatible, and offering precise control over particle size and degradation time. This enables personalised treatment tailored to individual patient needs. DSM's advanced properties provide significant advantages, including reduced risk of long-term complications, better tolerability, and enhanced clinical outcomes compared to permanent embolic materials.
"We are thrilled to embark on this clinical journey, which underscores our commitment to advancing the field of minimally-invasive therapies," said Helena Ossmer Thedius of Magle Group. "With DSM technology, we are uniquely positioned to address the unmet needs of osteoarthritis patients and deliver a solution that combines safety, efficacy, and innovation."
The study will be conducted at multiple centres in Europe, with collaboration from leading interventional radiologists and key opinion leaders in the field. It marks a pivotal step in Magle Group’s strategy to expand its portfolio and cement its position as a leader in degradable embolisation technologies.